Based on survival data previously reported for the BCIRG 006 study,
this presentation will describe how molecular subtypes of early stage
breast cancer could be used to identify appropriate Taxotere(R)-based
therapies, either with or without anthracyclines, for women with HER2
-- Two other oral presentations will discuss studies involving
anthracycline regimens with or without Taxotere(R):
Abst 78: "Preliminary results of the UK Taxotere(R) as Adjuvant Chemotherapy (TACT) Trial." Ellis PA, et al; United Kingdom. Sunday, December 16, 2007, 10:45 AM / General session 7, Exhibit Hall D The UK TACT Trial, a large multicenter phase III randomized trial compared four cycles of sequential FEC* followed by four cycles of Taxotere(R) 100mg/m2 every three weeks to standard UK operable breast cancer adjuvant chemotherapy (FEC* or E-CMF*) for eight cycles.
*FEC : Fluorouracil 600mg/m squared, Epirubicin 60 mg/m2 , and Cyclophosphamide 600 mg/m2 q 3wk x 8
E-CMF: Epirubicin 100 mg/m2 q3wk x 4 followed by Cyclophosphamide100 mg/m2 PO d1-14 or 600 mg/m2 IV d1-8, Methotrexate 40 mg/m2, and Fluorouracil 600 mg/m2 q 4wk x 4
Abst 72: "Three-year follow-up of trastuzumab following adjuvant
chemotherapy in node positive HER2-positive breast cancer patients: results
of the PACS-04 trial." Spielmann M, et al.
Sunday, December 16, 2007, 9:15 AM / General session 7, Exhibit Hall D
Following the PACS-01 trial, the PACS-04 randomized, multicenter,
phase III trial is designed to evaluate concomitant Taxotere(R) and
epirubicin versus a standard French chemotherapy regimen (FEC 100*) in
the adjuvant treatment of node-positive early breast cancer, and the
sequential use or not of trastuzumab for HER2 positive patients.
*FEC100: Fluorouracil 500 mg
Copyright©2007 PR Newswire.
All rights reserved